This clear connection between PHD2 and Treg function warrants further studies that explore the role of PHD2 in TME-associated immunosuppression and targeting of PHD2 could potentially lead to loss of tumor-induced immune tolerance, and hence, more efficient immunosurveillance. The gene discussed is EGLN1; the disease is neoplasm.